Illumina Corp (ILMN): יחס מחיר להכנסות

Illumina, Inc. (ILMN) generates revenue from the sale of DNA sequencing systems and associated reagents. The price-to-sales ratio reflects the market valuation of sales, with the latest value recorded as 6.90. The company assembles its instruments in-house while outsourcing a portion of the electronics. The rollout of NovaSeq X is currently supporting demand, while the impact of oncology diagnostics and legal costs remains moderate.
פילוחים אנליטיים של חברת Illumina Corp (ILMN)

The P/S metric determines the market value of a single unit of revenue, allowing for an assessment of the premium investors are willing to pay for current sales volume. The price-to-sales ratio trend reflects a revaluation of Illumina, Inc. (ILMN) amid intensifying competition in DNA sequencing and forced price reductions for services to maintain market share.